Literature DB >> 23378154

Challenging research on human subjects: justice and uncompensated harms.

Stephen Napier1.   

Abstract

Ethical challenges to certain aspects of research on human subjects are not uncommon; examples include challenges to first-in-human trials (Chapman in J Clin Res Bioethics 2(4):1-8, 2011), certain placebo controlled trials (Anderson in J Med Philos 31:65-81, 2006; Anderson and Kimmelman in Kennedy Inst Ethics J 20(1):75-98, 2010) and "sham" surgery (Macklin in N Engl J Med 341:992-996, 1999). To date, however, there are few challenges to research when the subjects are competent and the research is more than minimal risk with no promise of direct benefit. The principal reason given for allowing research that is more than minimal risk without benefit is that we should respect the autonomy of competent subjects. I argue that though the moral intuitions informing respect for autonomy are sound, there is another set of intuitions regarding what we take to be just treatment of another when one agent knowingly causes or allows suffering on another agent. I argue that concerns generated by commutative justice serve as limitations on permissible research. I highlight our intuitions informing this notion of justice by appealing to work done on theodicy; what counts as a morally sufficient reason for God to allow suffering in humans is applicable also to the researcher-subject relationship. I conclude that all human subjects who are exposed to more than minimal risk research should enjoy the same actual protections (e.g., subpart D) as those given subjects who cannot consent.

Entities:  

Mesh:

Year:  2013        PMID: 23378154     DOI: 10.1007/s11017-013-9241-9

Source DB:  PubMed          Journal:  Theor Med Bioeth        ISSN: 1386-7415


  24 in total

1.  What makes clinical research ethical?

Authors:  E J Emanuel; D Wendler; C Grady
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

Review 2.  Defining and describing benefit appropriately in clinical trials.

Authors:  N M King
Journal:  J Law Med Ethics       Date:  2000       Impact factor: 1.718

3.  When are research risks reasonable in relation to anticipated benefits?

Authors:  Charles Weijer; Paul B Miller
Journal:  Nat Med       Date:  2004-06       Impact factor: 53.440

4.  Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit.

Authors:  David Wendler; Leah Belsky; Kimberly M Thompson; Ezekiel J Emanuel
Journal:  JAMA       Date:  2005-08-17       Impact factor: 56.272

5.  The ethics and science of placebo-controlled trials: assay sensitivity and the Duhem-Quine thesis.

Authors:  James A Anderson
Journal:  J Med Philos       Date:  2006-02

6.  Facing up to paternalism in research ethics.

Authors:  Franklin G Miller; Alan Wertheimer
Journal:  Hastings Cent Rep       Date:  2007 May-Jun       Impact factor: 2.683

7.  Limits to research risks.

Authors:  F G Miller; S Joffe
Journal:  J Med Ethics       Date:  2009-07       Impact factor: 2.903

8.  How many "me-too" drugs is too many?

Authors:  Joshua J Gagne; Niteesh K Choudhry
Journal:  JAMA       Date:  2011-02-16       Impact factor: 56.272

9.  False hopes and best data: consent to research and the therapeutic misconception.

Authors:  P S Appelbaum; L H Roth; C W Lidz; P Benson; W Winslade
Journal:  Hastings Cent Rep       Date:  1987-04       Impact factor: 2.683

10.  Legitimate requests and indecent proposals: matters of justice in the ethical assessment of phase I trials involving competent patients.

Authors:  W M Kong
Journal:  J Med Ethics       Date:  2005-04       Impact factor: 2.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.